

August 02, 2022

The Manager  
Listing Department  
National Stock Exchange of India Limited  
Exchange Plaza, 5th Floor,  
Plot No. C-1, G- Block,  
Bandra - Kurla Complex, Bandra (East)  
Mumbai – 400 051

BSE Limited  
Corporate Relationship Department  
Floor 25, P.J. Towers,  
Dalal Street,  
Mumbai 400 001

Symbol: RPGLIFE

Scrip Code: 532983

Dear Sirs,

**Sub: Press Release - Financial Results**

Please find enclosed herewith a copy of press release with respect to Unaudited Financial Results of the Company for the quarter ended June 30, 2022.

Kindly take the above on record.

Thanking you,

Yours Sincerely,  
For RPG Life Sciences Limited

  
Rajesh Shirambekar  
Head – Legal & Company Secretary



Encl.: as above



**Q1 FY23 Revenue from operations grew by 19 % Y-o-Y and 24% Q-o-Q.  
PBT grew by 30% Y-o-Y and 130% Q-o-Q.**

**Mumbai, 02 August, 2022:** RPG Life Sciences Limited has announced its financial results for the quarter ended June 30, 2022.

Q1 FY23 Highlights	Y-o-Y Revenue from operations	Y-o-Y PBT
	Rs 128.93 crores – up from Rs 108.13 crores	Rs 25.12 crores – up from Rs 19.27 crores

RPG Life Sciences, engaged in the manufacturing and marketing of pharmaceutical products, posted a jump in PBT by 30% Y-o-Y and by 130% Q-o-Q for Q1 FY23. Revenue from operations at Rs 128.93 crores registered a growth of 19% Y-o-Y and a growth of 24% Q-o-Q for Q1 FY23. The Company maintained the upward trajectory in EBITDA margin, which improved from 21.6% to 22.5% Y-o-Y.

**Mr. Yugal Sikri, Managing Director, RPG Life Sciences Ltd.** said, “In Q1 FY23, the overall performance of the Company continued to be strong despite the geo-political challenges impacting supply chain and costs. Revenue and PBT grew by 19% and 30% respectively Y-o-Y. EBITDA margin retained its upward trajectory growing from 21.6% to 22.5% Y-o-Y.

Domestic Formulations business has recorded a robust growth both in value and volumes - significantly and consistently better than the market. While our comprehensive life cycle management program for legacy brands is helping them register healthy growth, our new product portfolio comprising of newer and progressive segments is also witnessing an impressive uptake. We have successfully forayed into a new therapy area - Rheumatology, which is strengthening our Specialty segment. Salesforce productivity continues to register healthy upward momentum. International Formulations business has shown a robust recovery while API business continue to register growth. Our unique digital initiative, RPGServ, is having impressive traction in physician connect and engagement. Going forward, we stay committed to implementing our Transformation Agenda to grow both topline and bottomline across segments.”

**RPG Life Sciences Ltd ([www.rpglifesciences.com](http://www.rpglifesciences.com)):**

RPG Life Sciences Ltd, part of RPG Enterprises, is an integrated pharmaceutical company operating in the domestic and international markets in the branded formulations, global generics and synthetic APIs space. The company is a research-based pharmaceutical company, producing a wide range of quality, affordable medicines. Its brands are highly trusted by healthcare professionals and patients.

**RPG Enterprises ([www.rpggroup.com](http://www.rpggroup.com)):**

RPG Enterprises, established in 1979, is one of India’s fastest growing business groups with a turnover of US\$ 4 Billion. The group has diverse business interests in the areas of Infrastructure, Tyres, Pharma, IT and Specialty as well as in emerging innovation-led technology businesses.

**Media Contact:**

Sumeet Chatterjee  
Senior Vice President – Corporate Brand and Group Communications  
+91 9820340650 | [sumeet@rpg.in](mailto:sumeet@rpg.in)

